TNF and infection: This may be due to evidence showing that systemic (oral) anti-TNF-α therapy in RA patients was shown to increase the risk of infections and malignancies by causing an overall immunosuppressive state [108] and that sustained i.a. delivery of a TNF-α inhibitor in a mouse tibial plateau fracture injury model negatively affected cartilage and bone healing [109,110].